BRCA1 and breast carcinoma: The BRCA1 mutant SUM149PT breast cancer cells had a lower mutation rate with 608 ± 146 acquired base substitutions, which again did not alter due to niraparib treatment (Fig. 2a and Table S1, p = 0.56).